UPDATED: Cytokinetics is getting its shot at a major PhIII showdown with Bristol Myers after posting positive data for a rare cardio disease. Shares rocket up
After losing a whole lot of market confidence in their lead drug, little Cytokinetics is now lining up for a crucial Phase III pivotal challenge for the next cardio drug in the pipeline. And that will put them toe-to-toe against powerhouse rivals at Bristol Myers Squibb, which just 9 months ago put down a $13 billion wager on what will likely be the first drug approved for the same rare cardio condition the biotech is contending for.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.